skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

European retrospective study of real-life haemophilia treatment

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.105 [Peer Reviewed Journal]

2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd. ;ISSN: 1351-8216 ;ISSN: 1365-2516 ;EISSN: 1365-2516 ;DOI: 10.1111/hae.13111 ;PMID: 27761962

Digital Resources/Online E-Resources

Citations Cited by
  • Title:
    European retrospective study of real-life haemophilia treatment
  • Author: Berntorp, E ; Dolan, G ; Hay, C ; Linari, S ; Santagostino, E ; Tosetto, A ; Castaman, G ; Álvarez-Román, M T ; Parra Lopez, R ; Oldenburg, J ; Albert, T ; Scholz, U ; Holmström, M ; Schved, J-F ; Trossaërt, M ; Hermans, C ; Boban, A ; Ludlam, C ; Lethagen, S
  • Subjects: Adult ; Clinical Medicine ; Europe ; Factor IX ; Factor VIII ; Haemophilia A ; Haemophilia B ; Hematologi ; Hematology ; Hemophilia A - therapy ; Humans ; Klinisk medicin ; Male ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Retrospective Studies ; Retrospective study ; Treatment
  • Is Part Of: Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.105
  • Description: Haemophilia treatment varies significantly between individuals, countries and regions and details of bleed rates, factor consumption and injection frequency are often not available. To provide an overview of the FVIII/FIX treatment practice and outcome for patients with haemophilia A (HA) or haemophilia B (HB) across Europe. Non-interventional, 12-month retrospective study where anonymized data were retrieved from haemophilia centres/registers in Belgium, France, Germany, Italy, Spain, Sweden and the United Kingdom. Male patients (all ages) receiving coagulation factor treatment 24 months prior to the study, with basal FVIII/FIX levels ≤5 IU dL , without inhibitors, were included. Data were summarized descriptively. In total, 1346 patients with HA and 312 with HB were included in the analysis; 75% and 57% had severe disease (FVIII/FIX < 1 IU dL ) respectively. Prophylaxis was most common for severe haemophilia, especially for children, whereas on-demand treatment was more common for moderate haemophilia in most countries. The mean (SD) prescribed prophylactic treatment ranged from 67.9 (30.4) to 108.4 (78.1) (HA) and 32.3 (10.2) to 97.7 (32.1) (HB) IU kg per week, across countries. Most patients on prophylaxis were treated ≥3 times/week (HA) or two times/week (HB). The median annual bleeding rate (ABR) for patients on prophylaxis ranged from 1.0 to 4.0 for severe HA, and from 1.0 to 6.0 for severe HB, while those with moderate haemophilia generally had slightly higher ABRs. Median ABRs for on-demand-treated severe HA ranged from 4.5 to 18.0, and for HB, 1.5 to 14.0. Treatment practice varied greatly between centres and countries and patients treated on-demand and prophylactically both experienced bleeds, emphasizing the need for further optimization of care.
  • Publisher: England
  • Language: English
  • Identifier: ISSN: 1351-8216
    ISSN: 1365-2516
    EISSN: 1365-2516
    DOI: 10.1111/hae.13111
    PMID: 27761962
  • Source: SWEPUB Freely available online
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait